Phasebio pharmaceuticals inc (PHAS)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Dec'17
Assets
Current assets:
Cash and cash equivalents

59,400

74,025

81,771

90,342

51,894

61,031

24,341

13,406

Restricted cash

-

-

-

-

20

20

-

20

Other receivables

896

1,233

583

1,180

670

233

411

-

Prepaid expenses and other assets

12,204

3,565

1,015

3,375

1,491

1,344

216

340

Total current assets

72,541

78,823

83,369

94,897

54,075

62,628

24,968

13,766

Property and equipment, net

2,637

1,924

1,022

677

380

355

251

302

Operating lease right-of-use assets

1,648

1,715

1,780

1,832

1,899

0

-

-

Deferred offering costs

-

-

-

-

-

-

2,218

-

Other assets

32

32

32

32

32

43

51

31

Total assets

76,858

82,494

86,203

97,438

56,386

63,026

27,488

14,099

Liabilities and stockholders' equity
Current liabilities:
Convertible promissory notes, net of discount

-

-

-

-

-

-

-

12,095

Derivative liability

-

-

-

-

-

-

-

3,028

Current portion of long-term debt

3,686

2,378

1,990

1,265

423

0

3,125

761

Accounts payable

1,918

2,921

1,659

3,047

2,058

1,806

1,576

430

Accrued expenses and other current liabilities

1,891

3,180

2,313

1,434

1,316

-

-

-

Accrued Liabilities, Current

-

-

-

-

-

2,771

2,987

1,281

Total current liabilities

7,495

8,479

5,962

5,746

3,797

4,577

7,688

17,595

Long-term debt, net

11,058

12,326

7,740

8,429

6,841

7,500

4,375

2,625

Operating lease liabilities, net

1,438

1,508

1,577

1,598

1,666

0

-

-

Development derivative liability

3,086

0

-

-

-

-

-

-

Other long-term liabilities

295

203

120

56

-

0

-

-

Preferred stock warrant liability

-

-

-

-

-

-

5,990

1,656

Deferred rent

-

-

-

-

-

22

-

5

Total liabilities

23,372

22,516

15,399

15,829

12,304

12,099

18,053

21,881

Commitments and contingencies (Note 8)

-

-

-

-

-

-

0

-

Redeemable convertible preferred stock, $0.001 par value; zero and 13,321,350 shares authorized at December 31, 2018 and 2017, respectively; zero and 9,131,999 shares issued and outstanding at December 31, 2018 and 2017, respectively.

-

-

-

-

-

-

125,609

89,633

Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding at March 31, 2020 and December 31, 2019

0

0

-

-

-

0

-

-

Common Stock, Value, Issued

29

29

29

29

25

25

1

1

Treasury stock, at cost, 29,967 shares as of March 31, 2020 and December 31, 2019

24

24

24

24

24

24

24

24

Additional paid-in capital

230,544

222,131

221,626

221,040

174,285

173,837

1,892

1,672

Retained Earnings (Accumulated Deficit)

-177,063

-162,158

-150,827

-139,436

-130,204

-122,911

-118,043

-99,065

Total stockholders’ equity

53,486

59,978

70,804

81,609

44,082

50,927

-116,174

-97,416

Total liabilities and stockholders' equity

76,858

82,494

86,203

97,438

56,386

63,026

27,488

14,099